tbuckley/cabot-search huggingface dataset:
CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).
Authors: Ellen M. Lavoie Smith, Herbert Pang, Constance Cirrincione, Stewart Barry Fleishman, Electra D. Paskett, Camilo E. Fadul, Chetaye Knox, Charles L. Shapiro, Paul Gilman
Journal: Journal of Clinical Oncology (2012)

CRA9013 Background: CALGB 170601 was a randomized, placebo-controlled phase III trial to determine whether duloxetine reduces painful chemotherapy-induced peripheral neuropathy (CIPN). The secondary study endpoint was treatment-related adverse events. Methods: The study used a double-blinded placebo-controlled crossover design with equally weighted randomization to one of two arms. Arm A participants received duloxetine followed by placebo. Arm B participants received placebo followed by duloxetine. The initial and crossover periods each consisted of six weeks of drug/placebo followed by one week of washout. Randomization was stratified by neurotoxic agent and high risk for developing painful CIPN. Eligible patients were 18 years or older with an average CIPN pain score &gt; 4/10 attributed to prior single agent taxane or platinum treatment. Participants took one capsule daily (30mg) for one week, and then two capsules (60mg) daily for four additional weeks. Participants completed the Brief Pain Inventory-Short Form (BPI-SF) at baseline and then weekly. The primary study endpoint was the change in BPI-SF scores within the initial treatment period. Analysis of covariance with an intent-to-treat approach was used to test the effect of treatment on change in pain score. Results: The target accrual goal (N = 231) was met, of which 185 (80%) completed the initial treatment period. Oxaliplatin was the most commonly received neurotoxic agent (59%). Individuals receiving duloxetine over the initial treatment period had a larger average decrease in pain score (mean change score = -1.09; S.E. = 0.19) than those receiving placebo (mean change score = -0.33; S.E. = 0.18) (p = 0.004). There was no difference in duloxetine efficacy based on the specific neurotoxic agent received. Severe (Grade 3) non-hematologic toxicity was reported by 11%, and 41% reported moderate (Grade 2) toxicities. The incidence of Grade 2+ fatigue, the most commonly reported side effect, was significantly higher in the duloxetine arm as compared to placebo (11% vs. 3%, p = 0.029). Conclusions: Duloxetine 60mg daily is an efficacious and well-tolerated intervention for the treatment of taxane or platinum-related painful CIPN.
THE BOYS OF NINETY-EIGHT.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"THE HUMAN LUNG: DID EVOLUTION GET IT WRONG?". J.B. WEST, R.R. WATSON AND Z. FU. EUR RESPIR J 2007; 29: 11-17.
Journal: European Respiratory Journal (2007)

12-mg formulation based on two 12-week studies [15, 16] and a 1-yr study in children aged 5-12 yrs [4].''The authors apologise for this error.
Performance of non-invasive fibrosis tests among non-alcoholic fatty liver disease (NAFLD) patients with normal alanine aminotransferase (ALT): data from a large North American primary care NAFLD pathway
Authors: Abdel-Aziz Shaheen, Stephen Congly, Wendy Schaufert, Kelly Burak, Alexandra Medellin, Deepak Bhayana, Mark G Swain
Journal: Journal of Hepatology (2020)
Diphenhydramine abuse and withdrawal
Authors: L. Glickman
Journal: JAMA (1986)

<h3>In Reply.—</h3> We appreciate the comments of Hall and colleagues. We believe our patient had superimposed acetaminophen hepatotoxicity because of the laboratory features and charac teristic centrilobular injury. She was taking no other hepatotoxic drugs (except alcohol) and had not knowingly been exposed to any other toxins. We agree that chronic liver disease alone does not predispose patients to hepatotoxicity from therapeutic acetaminophen use. She did not have any histologic or clinical evidence of cirrhosis. Rather, this case report describes an alcohol-abusing patient who developed centrilobular fibrosis while ingesting what she perceived to be a routine dose of acetaminophen—two extra-strength acetaminophen capsules every four hours. Potentiation of acetaminophen toxicity in chronic alcoholics receiving small doses of acetaminophen has been previously described.<sup>1,2</sup>Fasting also enhances experimental acetaminophen hepatotoxicity<sup>3</sup>and her dietary intake may have been poor. Other enzyme-inducing agents such as phenobarbital have also been shown to potentiate acetaminophen
Whiplash
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 16597: Economic Evaluations of PCSK9 Inhibitors in Reducing Cardiovascular Risk From Societal &amp; United States Payer Perspective
Authors: Khurram Nasir, Alejandro Arrieta, Emir Veledar
Journal: Circulation (2015)

Introduction: We aim to evaluate cost-effectiveness of recent FDA advisory committee recommended PCSK9 inhibitors for reducing cardiovascular disease (CVD) risk from societal &amp; U.S. third-party payer perspective. Methods: A Markov model was used to evaluate costs and effects associated with addition of PCSK9 inhibitor to standard of care (SOC) based on a) estimated 53% 1-year relative risk reduction (SOC 1 year CVD event rate: 2.18%, PCSK9 inhibitor+SOC: 0.95%), b) indirect annual CVD reduction probability (using Framingham risk) via mean 61% LDL lowering among at CV risk patients. The model considers cycles of 1 year. Post CVD events last 5 years, after that time individuals go back to treatment state if no subsequent CVD observed. Health state costs were derived from published evidence. Survival probabilities &gt;1 year were transformed to annual probabilities assumed on survival models. From societal perspective, cost per Quality-Adjusted Life Years (QALYs) gained are presented. We estimated payer’s perspective on net benefit balancing treatment vs. avoided cost and premium revenues over patient lifespan. Results: The table highlights societal gains and payer’s net benefit across range of estimated annual drug cost. At willingness-to-pay threshold of $100,000/QALY, PCSK9 inhibitors appear cost-effective if priced annually at $2500. At annual cost of $10,000, cost/QALY gained with PCSK9 inhibitor is nearly $400,000. From payer’s perspective, approximate net benefit was -$11,000 to -$51,000 per patient treated across annual drug cost range. Net benefits were only positive if treatment priced around $500/year. Conclusion: This study provides insights to facilitate discussion among healthcare stakeholders for considering future PCSK9 inhibitor’s utility balancing estimated benefits while accounting need for additional financial resources. Gaps between social &amp; private benefits need to be aligned for appropriate PCSK9 inhibitors adoption in U.S.
Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification
Authors: J. Calderaro, G. Couchy, S. Imbeaud, G. Amaddeo, J.-F. Blanc, C. Laurent, Y. Hajji, D. Azoulay, P. Bioulac-Sage, J. Zucman-Rossi
Journal: Journal of Hepatology (2017)
P2.01-18 Differential Molecular Mechanisms Associated with Dramatic and Gradual Progression in NSCLC Patients with Intrathoracic Dissemination
Authors: Y. Chen, B. Hua, W. Li, C. Zhang, W. Tang, A. Wang, X. Wu, J. Chen, J. Su, Y.W. Shao, Y. Wu, W. Zhong
Journal: Journal of Thoracic Oncology (2018)
Erratum: Evolution of GluN2A/B cytoplasmic domains diversified vertebrate synaptic plasticity and behavior
Authors: Tomás J Ryan, Maksym V Kopanitsa, Tim Indersmitten, Jess Nithianantharajah, Nurudeen O Afinowi, Charles Pettit, Lianne E Stanford, Rolf Sprengel, Lisa M Saksida, Timothy J Bussey, Thomas J O'Dell, Seth G N Grant, Noboru H Komiyama
Journal: Nature Neuroscience (2013)
Report on aortocoronary bypass graft surgery
Authors: R. J. Jones
Journal: JAMA (1979)

The American Medical Association's newest Council on Scientific Affairs (CSA) has come to age after three years of activity. After much discussion within the CSA and the AMA Board of Trustees, this Council has decided to enter the arena of health care technology assessment to deal with selected controversial procedures. In an effort to provide a voice that can speak with authority from the private sector on recent advances in medical procedures, the CSA has accepted the mandate to coordinate a program that will look, from time to time, at controversial medical procedures that have a broad impact on medicine. It plans to do this, henceforth, with the official help and advice of the various medical specialty organizations that may have an interest as determined through the agency of the AMA Interspecialty Advisory Board. A good example of the statements it plans to make is the report that appears in
Does the wedge hepatic vein pressure estimates the portal pressure in patients with NASH cirrhosis?
Authors: José Ferrusquía-Acosta, Octavi Bassegoda, Laura Turco, Enric Reverter, Juan Carlos Garcia Pagan, Isabel Graupera, Filippo Schepis, Marco Senzolo, Virginia Hernandez-Gea
Journal: Journal of Hepatology (2020)
Highlights
Journal: JAMA Dermatology (2019)

Preventing DHS in Patients With Leprosy 666 Dapsone hypersensitivity syndrome (DHS) is the most serious adverse event associated with dapsone administration and a major cause of death in patients with leprosy.In this cohort study of 1539 Chinese patients, Liu et al found that DHS did not develop in any HLA-B*13: 01-negative patients treated with dapsone.Prospective HLA-B*13:01 screening may reduce DHS incidence in the Chinese population.
Obstetrics and gynecology
Authors: G. R. Huggins
Journal: JAMA (1992)

In keeping with the American fascination for using high-tech medical procedures, treatment of early cervical neoplasia typically follows the sequence of (1) Papanicolaou test, (2) colposcopy, (3) biopsy, and, finally, (4) laser therapy. The use of colposcopy and colposcopy-directed biopsy as a diagnostic approach to cervical intraepithelial neoplasia (CIN) has eliminated the need for most cold-knife conizations of the cervix. The elimination of conizations has led to a significant decrease in hospitalization costs, a decrease in immediate operative morbidity, and elimination of potential harmful long-term effects of cervical stenosis on fertility. The majority of patients with CIN are women of reproductive age, and conservative management of these lesions is mandatory. Once a diagnosis of CIN is made, if the perimeters of the lesion can be visualized, most gynecologists will proceed with laser ablation of the cervix. Colposcopy-directed biopsies alone may fail to detect a significant number of lesions, including microinvasive
Psoriatic arthritis and aortic regurgitation
Authors: W. F. Muna
Journal: JAMA (1980)

CARDIAC lesions involving pericardium, myocardium, vascular components, conduction tissue, and valves have been described in most of the rheumatic or connective-tissue diseases. In classic rheumatoid arthritis, all of the cardiac components mentioned previously may be involved.<sup>1-4</sup>In ankylosing spondylitis, major cardiac involvement is usually limited to valvular and conduction tissue, with vascular, myocardial, and pericardial involvement occurring infrequently.<sup>3-6</sup>Although ankylosing spondylitis and psoriatic arthritis share several similar clinical and serological features, reports of either myocardial dysfunction or the nature of the cardiac lesion in psoriasis are rare.<sup>3,6-8</sup>We have recently seen a patient with long-standing HLA-B27-positive psoriatic arthritis who had chest pain and a new murmur of aortic regurgitation. Eventual surgical replacement of the aortic valve and histological examination of the resected native valve demonstrated pathological findings indistinguishable from those seen in ankylosing spondylitis. <h3>Report of a Case</h3> A 60-year-old man with a ten-year history of severe
ILLUSTRATIONS OF THE PATHOLOGY OF CANCER
Authors: J. Z. Laurence
Journal: BMJ (1856)

wIt, as shown in al our English hopils, ha had re- ain to the median operation of Ato , with quite gratifying results.An old nurse or sister", whose opinion on such a point may correct much false theory at present and much falser prejudice, has observed at Bartholomew's that all old stone cases die except Mr. Lloyd's.From what we have seen of all the smaller hospitals, and from time to time of Guy's, King's College fospital, St. Tho- mas's, the London Hospital, etc., there appears much sense and praetical value in this observation.Mr. HILTON has had, at Guy's Hospital, a case of ex- traction of stone in a female, where a hair-pin had been passed into the bladder.The case is doing very well.PORRIDABLE OPERATION ON THE JAW: RELATIVE VALUE OF CHLOROFORM AND ICE AS ANAM5THETICS.Msulerus etIafantunu, cap. 10.) Ambroise Pare seeks to impress the name by an actual drawing of a crab." D'autres auteurs out expliju6 ce nom par rapport & Is douleur rongeante quo cause cot horrible mal." (Tralti du Cancer, par ARiot.Paris: 1609.)+ To this cla belong Lebert and his followes t This second cbaracter, it may be noted, includes In Its terms the almost specific tendency exhibited by cancorous growts to infect the adjacent lymphatic glnds
Actinomycotic Empyema
Authors: H. W. Bowyer
Journal: BMJ (1949)

alo ofe atilepaaion enagdno-oi gthri glnsi ujct eieti 40 .MEl ev _I I 1-0 Z 1-5 l*7 1.9 Z*0 2-1 2-3 2.5 Z-7 3-0 312 PON4DERAL INDEX Graph showing percentage of each ponderal index.Sallstrbm, 1945)-and lid lag-2 1 in this series-may also offer a partial explanation.Other Findings.-Theoccurrence of 28 cases of greatly enlarged non-toxic thyroid glands in subjects resident in
Contents
Authors: Satish Kalhan, Elisabetta Bugianesi, Arthur Mccullough, Richard Hanson, David Kelley, Nicholas Tentolouris, Spyridon Pavlatos, Alexander Kokkinos, Despoina Perrea, Stamata Pagoni, Nicholas Katsilambros, Donatella Siepi, Simona Marchesi, Gaetano Vaudo, Graziana Lupattelli, Francesco Bagaglia, Matteo Pirro, Matteo Brozzetti, Anna Roscini, Elmo Mannarino, Johan Jocken, Ellen Blaak, Carla Van Der Kallen, Marleen Van Baak, Wim Saris
Journal: Metabolism (2008)
Correction
Authors: H Calwell, J King
Journal: BMJ (1952)

SIR,-The Medical Research Council's Dental ResearchUnit is in urgent need of certain post-mortem material for its investigations into dental and associated disease.In particular, the jaws, or parts of jaws, with teeth in situ, are required from healthy mouths; from cases with gingivitis but no other specific lesions; from cases of ulcerative stomnatitis; and from epileptics formerly under "epanutin " (sodium diphenyl hydantoinate) control.When,any of this material is or is likely to become available it is requested that this unit be notified (Telephone: Brixton 4744).
Who Dropped It?
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pigmented gut.
Authors: P. Grasso, R. Abraham
Journal: BMJ (1968)

psychosomatic diseases " have emotional sensitivity as their common property, and determinable specific sensitivities are found in most of them.The environment does the rest.-Iam, etc., RANYARD WEST.Church Stretton, Salop.Side-effects of Vinca Alkaloids SIR,-The findings by Dr. A. Vladutiu (22 June, p. 764) of acute dilatation of the gut in guinea-pigs receiving intraperitoneal injections of vinblastine is similar to the ex- perience of others working with this drug.Constipation, abdominal distension, and pain, sometimes sufficient to precipitate laparo- tomy, as well as acute urinary retention and loss of salivation, occasionally occur in patients receiving vinblastine,' 2 though the incidence of these complications is far greater in patients receiving the closely related alka- loid, vincristine.'' Prophylactic bulk laxa- tives and other aperients are recommended routinely for patients receiving vincristine.'Smith' found similar acute dilatation of the gut in mice treated with intraperitoneal injections of vinblastine, and moreover demonstrated degenerative changes in the myenteric plexus of the gut both in man and the mouse.This finding is in keeping with the known neurotoxicity of vinblastine, but more particularly of vincristine.'Almost certainly direct damage to the myenteric plexus causes paralysis of the gut.There is no evidence for the true ganglion-blocking action of vinblastine suggested by Dr.
Non-Ionizing Radiations: Biophysical and Biological Basis, Applications, and Hazards in Medicine and Industry
Journal: JNCI Journal of the National Cancer Institute (1985)

Journal Article Non-Ionizing Radiations: Biophysical and Biological Basis, Applications, and Hazards in Medicine and Industry Get access JNCI: Journal of the National Cancer Institute, Volume 74, Issue 4, April 1985, Page 953, https://doi.org/10.1093/jnci/74.4.953-c Published: 01 April 1985
BOOK REVIEWS
Authors: A. D. ELIAS
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article BOOK REVIEWS Get access Treatment of Soft Tissue Sarcomas. Herbert M. Pinedo, Jaap Verweij, eds. In: Cancer Treatment and Research ( W. L. McGuire, ed.). Boston: Kluwer Academic Publishers, 1989, 33 pp. $62.50. ANTHONY D. ELIAS ANTHONY D. ELIAS Dana Farber Cancer Institute44 Binney St. Boston, MA 02115 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 17, 6 September 1989, Pages 1329–1330, https://doi.org/10.1093/jnci/81.17.1329 Published: 06 September 1989
A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.
Authors: Michael Morse, Luis A. Diaz, Nilofer Saba Azad, Dan Laheru, Sherri Haley, Leanne Sophia Sleer, Philip M. Arlen
Journal: Journal of Clinical Oncology (2012)

233 Background: NPC-1C (NEO-101; ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment for pancreatic and colorectal cancers. This antibody was selected from a panel of hybridomas generated from mice immunized with semi-purified membrane-associated proteins derived from biologically screened, pooled human allogeneic colon cancer tissues. The NPC-1C target appears to be a variant of MUC5AC that is expressed specifically by human colon and pancreatic tumors with only occasional minimal cross-reactivity to certain GI tract tissues. Methods: A Phase 1/2A open label, multi-center dose escalation clinical trial with NPC-1C is currently accruing subjects with advanced pancreatic and colorectal cancer who are refractory to standard therapy. The primary objectives of the Phase I clinical trial are to determine the safety and tolerability of escalating doses of NPC-1C and to assess pharmacokinetics (PK) and select immune responses to the antibody at each dose level. Secondary objectives are to evaluate evidence of clinical benefit and to explore the immunologic correlates associated with administration of NPC-1C. Results: Three cohorts of subjects have been treated with NPC-1C at escalating dose levels of 1, 1.5, and 2 mg/kg IV every two weeks. Fourteen patients (9 colon, 5 pancreatic) have enrolled on study. At the 2 mg/kg dose level, at escalating rates of infusion, 3 subjects experienced mild to moderate hemolysis that resolved without intervention. Currently, 5 patients who have received 1.5 mg/kg at a constant rate of infusion have been evaluated, with no dose limiting toxicity. One of 3 patients re-staged thus far in the 1.5 mg/kg cohort showed stable disease on scans after completing the first course of treatment (4 doses). Preliminary data show no host induced antibody responses to the drug. Conclusions: NPC-1C is tolerated well at the current dose level of 1.5 mg/kg every 2 weeks. If no DLT is experienced by the 6 th subject in this cohort, we plan to continue accrual at this dose level to evaluate additional PK data, to assess dosing schedules, and to evaluate objective response rate, progression free survival, and overall survival in the phase 2A portion of this study.